| Assessment Status | Rapid Review Complete |
| HTA ID | 22041 |
| Drug | Pembrolizumab |
| Brand | Keytruda® |
| Indication | Is indicated in combination with chemotherapy with or without bevacizumab, for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS ≥1. |
| Assessment Process | |
| Rapid review commissioned | 16/06/2022 |
| Rapid review completed | 06/07/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab compared with the current standard-of-care. |
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.
